Company (location)

Company (location)

Value (M)

Type/product area

Terms/details

Date

NOVEMBER

Allied-Bristol Life Sciences LLC (Boston)

Synergy Partners R&D Solutions LLC

ND

Strategic partnership to offer insights to help Allied-Bristol identify the most promising early stage therapeutic opportunities at its academic research institution partners

Financial terms were not disclosed

11/19/14

European pharma industry

Innovative Medicines Initiative

$347.4

The pharma industry in Europe is uniting under the Innovative Medicines Initiative in a €280M (US$347.4M) program of Ebola virus research

IMI is a joint program between the European Union (EU) and the pharma industry, in which the EU provides grant funding for academic researchers and SMEs to take part in projects, while the industry provides in-kind resources; IMI is fast-tracking the Ebola research, asking for all proposals to be submitted by the end of November; it is hoped the first projects will start early in 2015; the focus will be on developing vaccines, scaling-up their manufacture, designing transport and storage systems, and managing vaccination programs

11/7/14

GE Healthcare (Chalfont St. Giles, UK)

Takeda Pharmaceutical Co. (Osaka, Japan)

ND

Alliance for research and development in the field of hepatic fibrosis

GE Healthcare will provide Takeda with its diagnostic imaging technology for use to generate a liver stiffness map as part of the research and development work

11/12/14

Intas Pharmaceuticals Ltd. (New Delhi)

Temasek (Singapore)

ND

Agreement under which Temasek acquired a 10.2% equity stake in Intas

Temasek acquired the stake by way of a secondary purchase of shares from private equity investor Chryscapital

11/11/14

Janssen Research & Development LLC (Raritan, N.J.)

The International Union Against Tuberculosis and Lung Disease

ND

Collaboration to include Sirturo in the STREAM study, a trial evaluating a treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis

Bedaquiline (Sirturo) is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults with pulmonary MDR-TB

11/7/14

Labcentral Inc. (Cambridge, Mass.)

Roche Diagnostics Corp. (Indianapolis; part of Roche AG)

ND

Agreement under which Roche will provide technology and financial support to Labcentral, a shared laboratory space

The space is designed as a launchpad for high-potential life sciences and biotech start-ups

11/13/14

Nuvo Research Inc. (Mississauga, Ontario)

Paladin Labs Inc. (Montreal)

ND

Agreement under which Nuvo reacquired Pennsaid 2% for osteoarthritis of the knee marketing rights to South America, Central America, South Africa and Israel for a noncash consideration

The company now owns all rights and will be seeking a partner or partners to market the drug internationally except in Canada, Russia and Greece where it already has marketing partnerships in place

11/14/14

Omega Pharma NV (Nazareth, Belgium)

Perrigo Co. plc (Dublin)

$4.5B

Agreement to acquire Omega

Perrigo agreed to acquire Omega for €3.6B (US$4.5B), comprising the purchase of Omega's equity for €2.48B and the assumption of €1.1B in debt

11/7/14

Pfizer Inc. (New York)

Merck KGaA (Darmstadt, Germany)

$2,85

Global deal for programmed death ligand 1 inhibitor MSB0010718C

The companies are pooling their resources, and Merck will take a 50% interest in Pfizer's PD-1 inhibitor program; they will share costs and revenues, and plan to initiate up to 20 immuno-oncology development programs next year, six of which could be pivotal studies; the deal is worth $850M up front and about $2B more in regulatory and commercial milestones

11/18/14

Qiagen NV (Hilden, Germany)

Novartis AG (Basel, Switzerland)

ND

Master collaboration agreement to develop and commercialize companion diagnostics to be paired with existing Novartis pharmaceutical products as well as compounds in its pipeline

The deal covers all Qiagen platforms, indications or biomarkers; financial terms were not disclosed

11/13/14

Scinopharm Taiwan Ltd. (Nanjing City, China)

Nanjing King-friend Biochemical Pharmaceutical Cof. Ltd. (Nanjing City, China)

ND

Research and development alliance to seek Chinese approval for the adenosine A2a receptor agonist regadenoson

The drug, approved by the FDA in 2008, is a stress agent indicated for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress; the partners expect to submit their application for approval of clinical trials in China in late 2015 and to reach commercialization by 2020; they will share profits after launch

11/11/14

UCB SA (Brussels)

Advent International Corp. (Boston) and Avista Capital Partners (New York)

$1.5B

Agreement to sell UCB's Kremers Urban Pharmaceuticals Inc. for about $1.5B

The transaction is expected to close by the first quarter of 2015

11/10/14

DECEMBER

Abbvie Inc. (North Chicago)

Medicines Patent pool

ND

Licensing deal for HIV meds lopinavir and ritonavir, enabling other companies and organizations to reformulate and manufacture specially designed LPV/r and r pediatric treatments

The deal is for distribution in low- and middle-income countries where 99% of children with HIV in the developing world live

12/2/14

Baxter International Inc. (Deerfield, Ill.)

Pfizer Inc. (New York)

ND

Agreement for acquisition of Baxter's portfolio of marketed vaccines

Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where those vaccines are manufactured

12/2/14

Contera Pharma ApS (Copenhagen)

Bukwang Pharmaceutical Co. Ltd. (Seoul, South Korea)

ND

Acquisition of Contera by Bukwang

The shareholders received an undisclosed up-front payment and are entitled to future contingent and royalty payments

12/2/14

Jitsubo Co. Ltd. (Tokyo)

Sosei Group Corp. (Tokyo)

ND

Sosei is acquiring Jitsubo for an undisclosed amount

Sosei said Jitsubo, a peptide technology specialist, would help it gain a foothold in what it expects by 2020 will become a $23B market for peptides, which may enable access to therapeutic targets that are difficult to control with small-molecule treatments

12/15/14

Oncodesign SA (Dijon, France)

Eisai Inc. (Woodcliff, N.J.)

ND

Agreement under which Oncodesign will conduct in vivo pharmacology studies and Eisai will provide gene expression profiling analysis using Oncodesign's xenograft models

They will investigate the potential of eribulin mesylate in earlier line treatment of metastatic breast cancer

12/18/14

Ono Pharmaceutical Co. Ltd. (Osaka, Japan)

Bristol-Myers Squibb Co. (New York) and Kyowa Hakko Kirin Co. Ltd. (Tokyo)

ND

Clinical trial collaboration agreement to conduct a phase I combination study of Opdivo, and the anti-CCR4 antibody, mogamulizumab, to treat patients with advanced or metastatic solid tumors

The planned combination study is designed help determine whether combining the immunotherapies can deliver better outcomes in patients with advanced cancers

12/11/14

Veropharm PAO (Russia)

Abbott Laboratories (Abbott Park, Ill.)

$305

Abbott acquired control of Russian pharmaceutical manufacturer Veropharm for 16.7B rubles (US$305M) through its purchase of Garden Hills LLC, the holding company that owns 98% of Veropharm

Abbott, which will fund the transaction with cash on the company's balance sheet, said the acquisition will allow it to establish a manufacturing footprint in Russia

12/15/14

JANUARY

Auden Mckenzie Holdings Ltd. (London)

Actavis plc (Dublin)

$461.4

Acquisition that includes a two-year royalty on a percentage of gross profits of one of Auden's products

Actavis is acquiring Auden with £306M (US$461.4M) on a debt-free basis, and the transaction will exclude Auden Mckenzie's real estate portfolio

1/27/15

Eli Lilly and Co. (Indianapolis)

Novartis Animal Health (Basel, Switzerland)

ND

Lilly completed its acquisition of Novartis Animal Health

Lilly funded the all-cash transaction of approximately $5.4B, including anticipated tax benefits, with approximately $3.4B of cash on hand and $2B in debt

1/5/15

Johnson & Johnson (New Brunswick, N.J.)

Leading global research institutions and nongovernment organizations

$115.7

Consortia to work in conjunction to accelerate the development its Ebola vaccine regimen

The Innovative Medicines Initiative plans to award those consortia grants totaling more than €100M (US$115.7M) from the Ebola+ program to support the development, manufacturing and patient education for the vaccine regimen

1/20/15

Meiji Seika Pharma Co. Ltd. (Tokyo) and Fedora Pharmaceuticals Inc. (Canada)

Roche AG (Basel, Switzerland)

$750

Licensing agreement for phase I candidate, OP0595, a beta-lactamase inhibitor that targets beta-lactamase enzymes in combination with new or existing beta-lactam antibiotics for use in difficult-to-treat bacterial infections

The deal means up to $750M in combined up-front, development, regulatory and sales-based milestone payments to Meiji Seika and Fedora; the companies also are entitled to tiered royalties; Roche gains global rights to develop and commercialize OP0595 except in Japan, where Meiji will retain sole commercialization rights

1/14/15

Munipharma Laboratories GmbH (Cambridge, UK) and Purdue Pharmaceuticals LP (Stamford, Conn.)

Laboratorios Esteve SA (Barcelona, Spain)

$1B

Global multiprogram discovery and development collaboration to bring to market next-generation products to manage pain

Mundipharma and Purdue could potentially make payments to Esteve exceeding $1M if all development, regulatory and sales milestones are met across programs

1/13/15

Mylan Laboratories Ltd. (India; subsidiary of Mylan Inc.)

South African National Department of Health

ND

Agreement for Mylan Laboratories' South African-based subsidiary Mylan Ltd. to supply antiretroviral medications from April 1, 2015, to March 31, 2018

Mylan will supply the South African government with triple therapy fixed dose combination treatments

1/2/15

Prasco Laboratories Inc. (Cincinnati)

Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) and its subsidiary

ND

Distribution and supply agreement for rights to distribute authorized generic colchicine tablets, a version of Colcyrs (colchicine, URL Pharma Inc.)

Terms were not disclosed

1/13/15

Roche AG (Basel, Switzerland)

Qiagen NV (Venlo, the Netherlands)

ND

Agreement that includes a provision of nonexclusive licenses to recently granted Roche patents pertaining to the detection of mutations in the EGFR pathway, including in the KRAS gene

Financial details were not disclosed

1/15/15

Solasia Pharma K.K. (Tokyo)

Meiji Seika Pharma Co. Ltd. (Tokyo)

ND

Exclusive global license for rights to commercialize, distribute and promote darinaparsin for patients with relapsed and refractory peripheral T-cell lymphoma in Japan in exchange for an undisclosed initial development payment

Meiji also obtained the right to develop and commercialize darinaparsin for other indications in Japan, the option to manufacture intravenous formulation of darinaparsin and a right of first negotiation relating to the formulations other than the intravenous formulation of darinaparsin

1/21/15

Tianyin Pharmaceutical Co. Inc. (Chengdu, China)

Undisclosed industrial partner

ND

Alliance to form an integrated platform based on Tianyin's modernized traditional Chinese medicine franchise and focused primarily on the cardiovascular agent Gingko mihuan

TPI's wholly owned subsidiary, Chengdu Tianyin Pharmaceutical, will own a majority stake in the alliance, which will integrate TPI's existing sales force with network resources from the undisclosed partner

1/5/15

FEBRUARY

Actavis plc (Dublin)

Astrazeneca plc (London)

$700

Agreement under which Astrazeneca will acquire the rights to Actavis' branded respiratory business in the U.S. and Canada for initial consideration of $600M and low single-digit royalties above a certain revenue threshold

Astrazeneca will gain rights to Tudorza Pressair (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist for chronic obstructive pulmonary disease (COPD), and Daliresp (roflumilast), a once-daily oral PDE4 inhibitor currently on the market for COPD; Astrazeneca will pay Actavis an additional $100M, and Actavis has agreed to a number of contractual consents and approvals, including certain amendments to the ongoing collaboration agreements between Astrazeneca and Actavis; the transaction is set to complete this quarter

2/6/15

Actavis plc (Dublin)

Mayne Pharma Ltd. (Greenville, N.C.)

$50

Agreement under which Actavis will divest U.S. rights to the Doryx brand acne treatment and related assets to Mayne for about $50M

Actavis will continue to package, distribute and actively promote the product for a transition period until May 2 following close of the deal

2/11/15

Actavis plc (Dublin)

TPG (Fort Worth, Texas)

ND

Agreement for Actavis to divest Aptalis Pharmaceutical Technologies, or Pharmatech, to the investment firm

Financial details were not disclosed

2/17/15

Alk-Abello A/S (Copenhagen)

Biocsl Inc. (King of Prussia, Pa.)

ND

Partnership in Australia and New Zealand, granting Biocsl exclusive rights to promote and sell Alk's SLIT-tablets against house dust mite and grass pollen allergy, and ALK's Jext adrenaline auto-injector

Alk will receive an undisclosed up-front payment, followed by a milestone payment upon approval of the HDM SLIT-tablet in Australia; ALK will sell products to Biocsl at a pre-agreed price structure ensuring a certain split of the final in-market revenues generated by Biocsl

2/10/15

Cyclenium Pharma Inc. (Sherbrooke, Quebec)

Fundacion Centro de Excelencia en Investigacion de Meciamentos Innovadores en Andalucia (Granada, Spain)

ND

Drug discovery and collaboration agreement to use Cyclenium's library of macrocyclic molecules in concert with Fundacion Medina's infective disease research expertise to discover new anti-infective drug candidates effectives against bacterial and fungal pathogens

Terms were not disclosed

2/24/15

Ferring Pharmaceuticals SA (Saint Prex, Switzerland)

Ctcbio Inc. (Seoul, South Korea)

ND

Agreement to acquire rights to an unnamed oral drug delivery technology

Deal includes an up-front payment, milestones and royalties; the two companies will collaborate to develop prototype formulations for in-vitro and in-vivo testing and the subsequent up-scaling required to manufacture the technology to meet worldwide good manufacturing practice requirements

2/24/15

Helsinn Group (Lugano, Switzerland)

Stendhal International (Mexico City)

ND

Exclusive rights deal for the distribution and marketing of netupitant-palonosetron (NEPA) to prevent chemotherapy-induced nausea and vomiting

Helsinn retains all international regulatory and clinical development activities and the supply of NEPA for commercial use; Stendhal will be responsible for all distribution and marketing activities in the designated territories

2/3/15

Helsinn Group (Lugano, Switzerland)

Mundipharma International Corp. Ltd. (Singapore)

ND

Exclusive distribution and licensing agreement of NEPA, an oral fixed combination of netupitant and palonosetron developed to prevent chemotherapy-induced nausea and vomiting, in Brazil

Helsinn retains all international regulatory and clinical development activities and the supply of NEPA for commercial use; Mundipharma will have rights related to marketing, promotion and sales of NEPA in the designated territory

2/10/15

Helsinn Group (Lugano, Switzerland)

Mundipharma International Corp. Ltd. (Singapore)

ND

Exclusive agreement for the distribution and licensing of NEPA, an oral fixed combination of netupitant and palonosetron to prevent chemotherapy-induced nausea and vomiting, in Brazil

NEPA is an oral fixed combination of a novel NK1 receptor antagonist (netupitant) and the best-in-class 5-HT3 receptor antagonist palonosetron, already approved as a combination in the U.S. with the trade name Akynzeo for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

2/12/15

Hospira Inc.

Pfizer Inc. (New York)

$17B

Pfizer agreed to acquire Hospira for $90 per share in cash, or $17B

The price represents a 39% premium to the closing price for Hospira's shares on Feb. 4

2/6/15

Intellipharma-ceutics International Inc. (Toronto)

Teva Pharmaceuticals USA Inc. (North Wales, Pa.)

ND

Agreement granting Teva an exclusive license to market in the U.S. an undisclosed extended-release drug product candidate

Under the agreement with Teva, subject to certain conditions, Intellipharmaceutics has agreed to manufacture and supply the product exclusively for Teva and Teva has agreed that Intellipharmaceutics will be its sole supplier of the product to be marketed in the U.S.

2/3/15

Jiangyin Tianjiang Pharmaceutical Co. Ltd. (Jiangyin, China)

China Traditional Chinese Medicine Co. Ltd. (Hong Kong)

$1.3B

Chinese Traditional Chinese Medicine is acquiring 81% of traditional Chinese medicine manufacturer Jiangyin

The TCM arm of Chinese state-owned Sinopharm Group is paying $1.3B

2/5/15

Merck & Co. Inc. (Whitehouse Station, N.J.)

Medicines Patent Pool

ND

Agreement to license its pediatric formulations of raltegravir for use in treating HIV-1 infection in infants and children, ages 4 weeks to younger than 12 years, in developing countries

The deal also allows for the development of pediatric formulations of raltegravir and novel combinations; raltegravir is marketed by Merck as Isentress

2/25/15

Merck KGaA (Darmstadt, Germany)

Bristol-Myers Squibb Co. (New York)

ND

Agreement for BMS to transfer full responsibility for the promotion of Erbitux (cetuximab) in Japan effective May 1

Erbitux was launched in collaboration with BMS in Japan in September 2008 to treat metastatic colorectal cancer, followed by an additional indication in head and neck cancer in December 2012

2/17/15

Moberg Pharma AB (Stockholm)

Berlin-Chemie AG (Berlin; a member of the Menarini Group)

ND

Exclusive rights agreement to market and sell Emtrix in Russia and Ukraine

Emtrix is an over-the-counter topical product for the local treatment of onychomycosis

2/10/15

Mylan Laboratories Ltd. (India; subsidiary of Mylan Inc.)

Famy Care Ltd. (Mumbai, India)

$750

Agreement to acquire the female health care businesses from Famy Care for $750M in cash plus additional contingent payments of up to $50M

The acquisition will build on Mylan's existing partnerships with Famy Care in North America, Europe and Australia, and provide Mylan with an enhanced and now vertically integrated platform that will accelerate the company's growth in women's health care

2/3/15

Pfizer Inc. (New York)

Alzheimer's Drug Discovery Foundation

ND

Agreement to advance the development of new small-molecule drugs for Alzheimer's disease and related dementias

As part of the first-of-its kind collaboration in Alzheimer's, the ADDF and CTI will jointly invest in translational research projects, with a focus on novel Alzheimer's drug targets

2/12/15

Notes

The date indicated refers to the BioWorld Today issue in which the news item can be found.